

IN THE CLAIMS

1. (currently amended) A pharmaceutical tablet comprising fosinopril sodium and the lubricant zinc stearate wherein the presence of the lubricant results in a significant reduction in products of degradation for the tablet in comparison to other known lubricants such as magnesium stearate, and calcium stearate.

claims 2 to 5 (cancelled)

6. (currently amended) A The tablet as in ~~of~~ claim 1 further comprising lactose.
7. (currently amended) A tablet as in claim 1 ~~or 6~~ wherein the amount of lubricant by weight is from about about 0.3 percent to about 4.0 percent of the total tablet weight.

Claims 8 to 10 (cancelled)

11. (New) A tablet as in claim 6 wherein the amount of lubricant by weight is from about about 0.3 percent to about 4.0 percent of the total tablet weight.
- 12.(New) A pharmaceutical tablet comprising fosinopril sodium and the lubricant zinc stearate in the amount by weight from about 0.3 percent to about 4.0 percent of the total tablet weight and wherein the presence of zinc stearate results in a significant reduction in products of degradation for the tablet in

comparison to other known lubricants such as magnesium stearate, and calcium stearate.

13. (New) The tablet of claim 12 further comprising at least one excipient selected from lactose, microcrystalline cellulose, starch, croscarmellose sodium, sodium starch glycolate, crospovidone, or colouring.